Exosome demand is up 48%. The word itself is banned.
Our daily index shows exosome demand up 48.5% over two months. Yet since January 2025 Korea bars the word "exosome" on a cosmetic label unless the source is named. Here are the five questions to ask a Korean factory before you take a quote.
Exosome cosmetics are an ingredient where demand and labelling rules move in opposite directions. In our daily collection the exosome demand index rose from 1.34 to 1.99 between 16 July and 27 September 2026, up 48.5%. But Korea's Guideline on Cosmetic Labelling and Advertising, revised on 22 January 2025, bars the bare terms "exosome" and "exosome cosmetic". Source-named forms such as "plant exosome" or "milk exosome" are allowed, and human-derived material must meet the Human Cell and Tissue Culture Fluid safety standard in Appendix 3 of the Cosmetic Act, with records kept for three years.
Demand is rising
This is our daily ingredient demand index over the 64 days from 16 July to 27 September 2026.
| Ingredient | From | To | Change |
|---|---|---|---|
| Hyaluronic acid | 30.70 | 53.77 | +75.1% |
| Exosome | 1.34 | 1.99 | +48.5% |
| Centella | 2.18 | 2.68 | +22.7% |
| Retinol | 21.80 | 24.57 | +12.7% |
| Niacinamide | 55.80 | 44.81 | −19.7% |
| PDRN | 11.72 | 9.00 | −23.2% |
While PDRN, the hottest ingredient of the past year, fell 23.2%, exosomes rose 48.5%. The absolute size is still small: an index of 1.99 is about 4% of niacinamide's 44.81. That makes it a small lane with a clear direction, not a crowded one.
The seasonal pattern agrees. Exosome interest starts rising in August and peaks in January, and the current move sits inside that pattern rather than against it.
But you cannot print the word in Korea
This is the part overseas buyers most often miss.
On 22 January 2025 the Ministry of Food and Drug Safety revised its Guideline on Cosmetic Labelling and Advertising to prohibit any expression that could lead a consumer to believe a product contains human-derived stem cells or specific human-derived components such as exosomes or liposomes.
| Wording | In Korea |
|---|---|
| "Exosome cosmetic" | Prohibited |
| "Exosome" on its own | Prohibited |
| "Plant exosome" | Allowed |
| "Milk exosome" | Allowed |
The same revision also barred "hospital use only", "for dermatology procedures", "microneedle", and skin-age claims such as "skin age reduced by 10 years".
So making the product and printing the word are two separate matters. Hand overseas marketing copy straight to a Korean OEM and it comes back at the labelling stage. Naming the source in front of the word usually resolves it.
Choosing human-derived brings paperwork
If you go with human cell culture fluid, Appendix 3 of the Regulation on Safety Standards for Cosmetics applies. Your manufacturer must hold:
- donor eligibility test records
- collection, testing and culture records for the human cells
- toxicity test data and the other records and certificates the standard requires
- all of the above kept for three years from the date the finished product was made
This is enforced. When the ministry inspected the 36 largest manufacturers by output, representing 75% of the market, in September 2023, three were found to have failed the duty to prepare and retain these records, and a three-month suspension of sales operations was requested for a first offence.
Read that paragraph as a buyer's checklist: ask any factory proposing human-derived material to show you those four things. A factory that cannot is not ready to use the ingredient.
The destination market decides the source
| Market | Human-derived | Plant or milk-derived |
|---|---|---|
| Korea | Allowed if the safety standard is met | Allowed |
| EU | Prohibited (Regulation 1223/2009, Annex II) | No specific restriction |
| China | Prohibited (2015 Safety and Technical Standards) | No specific restriction |
| United States | No specific requirement | No specific requirement |
| Taiwan | Case-by-case exceptions since 2024 | Allowed |
In one line: if the EU or China is anywhere in your plan, start with plant or milk-derived material. Developing on human-derived material and switching the source later means reformulating, not relabelling.
Naming is already settled. As of 14 May 2025 the wINCI database listed 28 exosome-related INCI names, covering human, animal and milk-derived sources. A listing means the name exists; permission still varies by country.
The ingredient list will not tell you the dose
Exosomes rarely appear on an ingredient list under that word. They usually enter as an extract, a culture fluid or a filtrate. On top of that, Korean ingredient lists may order everything below 1% freely, so taking a competitor's ingredient list apart will not tell you how much is in there.
Ask for these two documents at the quotation stage:
- the source and the process — plant, milk or human, and how the vesicles were separated
- a quantitative test report such as particle count per millilitre, with the testing lab named
A quote without them may simply be the cheap one. You can check where a candidate ingredient's demand is heading in today's ingredient signals first.
In short
- Our exosome demand index rose 48.5% between 16 July and 27 September 2026, while PDRN fell 23.2%
- Since 22 January 2025 Korea bars the bare word "exosome"; naming the source, as in "plant exosome", is allowed
- Human-derived material falls under the Appendix 3 safety standard with three-year record retention (3 of 36 inspected manufacturers were cited in September 2023)
- The EU and China prohibit human-derived material, so fix the market before the source
- Concentration is invisible on an ingredient list, so ask for a quantitative test report
Once the source and the market are set, the product planner returns an estimated cost and a sample request within a day.
*Sources: MFDS Guideline on Cosmetic Labelling and Advertising, revision of 22 January 2025, as reported by Cosin Korea and Bosa; Appendix 3, Regulation on Safety Standards for Cosmetics (Human Cell and Tissue Culture Fluid); MFDS inspection results of September 2023 as reported by Newsis and Cosmorning; REACH24H, "INCI Registration for Exosome Ingredients" (as of 14 May 2025); CIRS review of global exosome cosmetic regulation. Demand index figures are from our own daily collection across Olive Young, Hwahae and NAVER DataLab, updated 28 September 2026.*
Questions people ask
Making them is. But human-derived material must meet the safety standard in Appendix 3 of Article 8 of the Cosmetic Act, and writing only "exosome" on the label or in advertising is a prohibited expression under the guideline revised on 22 January 2025. Source-named forms such as "plant exosome" are permitted.
Not if it is human-derived. The EU prohibits human-derived ingredients under Annex II of Regulation 1223/2009, and China's 2015 Safety and Technical Standards for Cosmetics bars human-derived material as a cosmetic ingredient. Plant and milk-derived exosomes face no specific restriction in either market. Taiwan began granting case-by-case exceptions after 2024.
No. Exosomes usually appear under an extract, culture fluid or filtrate name, and the word "exosome" does not show up at all. Concentration is not visible from an ingredient list, so ask the supplier for a quantitative test report such as particle count per millilitre.
Yes. As of 14 May 2025 the wINCI database listed 28 exosome-related INCI names, covering human, animal and milk-derived material. But an INCI listing means a name exists, not that the market you sell into allows it.
The demand side looks acceptable. Our index rose 48.5% over two months, and the ingredient's seasonal pattern starts rising in August and peaks in January, so the current move fits. The safer order is to fix the destination market and the regulatory route first, then choose the source — plant, milk or human.